U.S. Contraceptives Market - By Product, By Age Group, By Distribution Channel - Forecast, 2024 – 2032

U.S. Contraceptives Market Size

U.S. contraceptives market size was valued at around USD 7 billion in 2023 and is expected to exhibit growth at a CAGR of 7.2% from 2024 to 2032. Contraceptives, also known as birth control methods, are various types of devices and drugs used to prevent pregnancy by intentionally inhibiting or reducing the chances of conception. The market encompasses a range of contraceptive methods, including condoms, IUDs, vaginal rings, pills, and more.
 

A prominent trend in the market is the growing preference for long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and contraceptive implants. Additionally, hormonal contraceptives like oral contraceptive pills remain popular, though innovations such as non-hormonal gels are gaining traction, appealing to individuals who prefer non-hormonal options.
 

Another key trend is the expansion of over-the-counter (OTC) access to contraceptives. In 2023, the FDA approved Opill, a progestin-only oral contraceptive, for OTC sales—a move expected to improve accessibility, particularly for younger women and those in rural areas. This approval reflects a broader push for policy changes aimed at reducing barriers to contraception, aligning with efforts under the Affordable Care Act, which mandates insurance coverage for contraceptive methods without out-of-pocket costs.
 

Telemedicine platforms are also influencing the market, with companies like Nurx and Planned Parenthood Direct offering convenient mail-order birth control services, especially in the wake of the COVID-19 pandemic.
 

Meanwhile, the male contraceptive market is slowly emerging, with clinical trials for non-hormonal male contraceptives, such as the Vasalgel injection, showing promise, though widespread availability remains several years away. These trends indicate an evolving market that prioritizes accessibility, innovation, and diverse consumer preferences.
 

U.S. Contraceptives Market Trends

The U.S. contraceptive market is experiencing notable trends driven by evolving consumer preferences, technological advancements, and regulatory shifts. One significant trend is the increasing demand for long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and subdermal implants. These methods are favored for their high efficacy and convenience, requiring minimal user intervention once in place. For instance, the IUD market segment is expected to grow significantly, driven by products like Bayer's Mirena and CooperSurgical's ParaGard.
 

• The rise of telemedicine has also profoundly impacted the contraceptive market. Companies like Nurx and Planned Parenthood Direct offer online consultations and home delivery of birth control pills, appealing to tech-savvy, convenience-seeking consumers. According to a 2023 report by the Guttmacher Institute, approximately 29% of women in the U.S. who use contraceptives opted for telehealth services, up from just 10% in 2019.
   
• Innovation in contraceptive methods is another key trend. The approval of new products, such as Annovera—a reusable vaginal ring providing a year of contraception—exemplifies the market's push towards solutions that offer both efficacy and user-friendliness. Additionally, the development of male contraceptives, though still in experimental stages, indicates a broadening scope in the market, potentially addressing gender equity in contraceptive responsibility.
   
• Regulatory changes also play a crucial role. The FDA's approval of over-the-counter (OTC) sales for certain contraceptive methods without a prescription marks a significant shift, aimed at increasing accessibility and reducing barriers to birth control. For example, the approval of Opill, an OTC daily birth control pill, is expected to cater to a broader audience, particularly those facing challenges in accessing healthcare services.
   

U.S. Contraceptives Market Analysis

Based on product type, the market is bifurcated into drugs and devices. The drugs segment dominated the market with a revenue of around USD 3.8 billion in 2023.
 

• Contraceptive drugs, when used correctly and consistently, are highly effective in preventing pregnancy. They provide individuals with a reliable method of birth control, allowing them to plan and space pregnancies according to their personal preferences and circumstances.
   
• Contraceptive drugs offer convenience and ease of use; methods such as oral contraceptive pills or patches can be self-administered at home without the need for medical intervention. This allows individuals to maintain control over their reproductive health and make informed decisions about contraception.
   
• Another significant driver is the development of new and improved contraceptive formulations that address user concerns about side effects and efficacy. Innovations such as extended-cycle pills, which reduce the frequency of menstrual periods, and low-dose hormonal options, which aim to minimize adverse effects, are gaining traction. The FDA's approval of new hormonal products, like the extended-cycle pill Annovera, reflects the trend toward providing more flexible and convenient options for users.
   

Based on age group, the U.S. contraceptives market is branched into 15-44 years, and above 44 years. The 15-44 years segment dominated the market with a revenue of around USD 6.5 billion in 2023.
 

• The 15–44 years age group is generally referred to as the reproductive or childbearing age group. This demographic plays a significant role in driving the demand for contraceptives. Adolescents and young adults often engage in sexual activity, and many are not yet ready to start families due to educational, career, or personal reasons. Contraceptives provide them with a means to prevent unintended pregnancies while pursuing other life goals.
   
• This age group often has better access to healthcare facilities and services, making it easier for them to obtain contraceptives. Contraceptives can offer health benefits beyond family planning, such as reducing the risk of certain health issues like ovarian and endometrial cancers. Many healthcare providers offer contraceptive counseling and services to help individuals make informed choices.
   

Based on distribution channel, the U.S. contraceptives market is segmented into retail pharmacies, hospital pharmacies, online channels, and other distribution channels. The retail pharmacies segment dominated the market in 2023 with a share of 45.9%.
 

• Retail pharmacies are easily accessible to the general population. People can visit their local pharmacies without needing an appointment, making them a convenient source for contraceptives. This accessibility promotes increased usage and drives market demand.
   
• Retail pharmacies can dispense both prescription and over-the-counter contraceptives, providing individuals access to a wide array of contraceptive options, regardless of whether they have a prescription. Additionally, retail pharmacies often run promotions, discounts, and loyalty programs that make contraceptives more affordable and encourage their use.
   
• Some insurance plans cover the cost of prescription contraceptives, and retail pharmacies can process insurance claims, making it easier for individuals to afford contraception.
   

East South Central contraceptives market accounted for USD 1.7 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.9% between 2024 and 2032 period.
 

• High rates of unintended pregnancies and increased awareness about family planning have led to growing demand for contraceptives in various states. Government initiatives and public health campaigns play a crucial role in increasing access to contraceptives in the East South-Central region.
   
• The rising popularity of long-acting reversible contraceptives (LARCs), such as IUDs and implants, is another key driver in this region. LARCs are increasingly preferred for their high effectiveness and convenience, with healthcare providers offering them as a viable solution to reduce unintended pregnancies.
• Furthermore, nonprofit organizations and community-based health initiatives have bolstered awareness and education around reproductive health, particularly for underserved populations.
   

West South-Central contraceptives market is projected to grow remarkably in the coming years.
 

• The West South-Central contraceptives market, encompassing Texas, Louisiana, Oklahoma, and Arkansas, is expected to grow remarkably due to several key drivers. Population growth and a large reproductive-age demographic in states like Texas, the second most populous U.S. state, are primary factors fueling demand for contraceptives. Growing awareness of family planning and sexual health in both urban and rural areas is also driving the market, with increased education efforts from public health organizations and clinics like Planned Parenthood playing a significant role.
   
• Another key driver is the focus on improving access to contraceptives through Medicaid expansions and government-backed programs. In Texas, initiatives like the Healthy Texas Women Program provide free birth control to low-income women, significantly boosting access to various contraceptive methods.
   
• Additionally, changing social and cultural attitudes around reproductive health are influencing the market, with younger generations seeking more control over family planning and reproductive choices. Despite regional challenges around access to reproductive healthcare, efforts to expand contraceptive access and the growth of e-commerce channels for contraceptive distribution are expected to continue driving market growth in the West South-Central region.
   

U.S. Contraceptives Market Share

The market is highly competitive, with several key players dominating the landscape. Long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and contraceptive implants, have gained substantial market traction due to their high efficacy and long-term use. In addition to LARCs, the oral contraceptive pills segment remains one of the most widely used forms of birth control.
 

However, the increasing availability of over-the-counter (OTC) options and telemedicine platforms, such as Nurx and SimpleHealth, is reshaping the market by providing easier access to contraceptives. The growth of e-commerce and online prescription services has also captured a significant portion of the market, particularly among younger consumers, contributing to the diversification of market share across different segments.
 

U.S. Contraceptives Market Companies

Some of the eminent market participants operating in the U.S. Contraceptives industry include:

• Allergan (AbbVie, Inc.)
• Ani Pharmaceuticals
• Bayer AG
• CooperSurgical Inc
• Church & Dwight Co, Inc.
• Johnson & Johnson
• Mayer Laboratories, Inc.
• Merck & Co., Inc.
• Meril Life Sciences Pvt. Ltd.
• Perrigo Company
• Pfizer, Inc.
• Pregna International Ltd.
• Reckitt Benckiser Group Plc.
• Teva Pharmaceuticals Industries Ltd.
• Veru Inc.
   

U.S. Contraceptives Industry News:

• In October 2022, Bayer received a grant from the Bill & Melinda Gates Foundation to support the development of non-hormonal contraceptive methods. This partnership enhanced the research in this area, reflecting Bayer's commitment to expanding contraceptive options.
   
• In December 2022, CooperSurgical, Inc. announced a strategic partnership with Ostro to launch a new consumer engagement solution for CooperSurgical's hormone-free IUD, Paragard. This partnership helped the company incorporate advanced technology including live nurse navigator to assist patients and Paragard users, as a result enhancing their customer base and gaining a technological advantage over its peers.
   

U.S. contraceptives market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Drugs
  • Oral contraceptive pills
  • Injectable contraceptives
  • Topical contraceptives
• Devices
  • Intra-uterine devices
    • Hormonal IUD
    • Copper IUD
  • Condoms
    • Male
    • Female
  • Subdermal implants
  • Vaginal rings
  • Diaphragms
  • Contraceptive sponges

Market, By Age Group

• 15-44 years
• Above 44 years

Market, By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online channels
• Other distribution channels

The above information is provided for the following zones:

• East North Central
• West South Central
• South Atlantic
• Northeast
• East South Central
• West North Central
• Pacific Central
• Mountain States